secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-08-07T12:30:17+00:00
Accession:  0001493152-26-036486
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Q2 revenue up 19% to $1.5M; CyPath Lung volume +216% YoY
--------------------------------------------------------------------

- Q2 2026 revenue $1.5M, up 19% YoY; net loss narrowed to $3.4M from $4.1M.
- CyPath Lung test volume +216% YoY; H1 revenue from test +159% to ~$835k; 1,097 reports vs 390.
- Cash and equivalents $2.4M at June 30, 2026 vs $6.4M at Dec 31, 2025; completed $3.2M public offering in June.
- Pipeline: asthma/COPD diagnostics and skin cancer therapeutics; longitudinal trial at 11 sites incl. VA.
- Physician offices ordering test up 122%; existing clients' orders +71% H1 YoY.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226036486/0001493152-26-036486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226036486/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-036486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer